Integration of clinical phenoms and metabolomics facilitates precision medicine for lung cancer

作者：Furong Yan, Chanjuan Liu, Dongli Song, Yiming Zeng, Yanxia Zhan, Xibing Zhuang, Tiankui Qiao, Duojiao Wu, Yunfeng Cheng, Hao Chen · 发表于：Cell Biology and Toxicology · 年份：2024 · DOI：10.1007/s10565-024-09861-w · 被引用次数：11 · 研究领域：Lung Cancer Diagnosis and Treatment、Metabolomics and Mass Spectrometry Studies、Lung Cancer Treatments and Mutations

Abstract Lung cancer is a common malignancy that is frequently associated with systemic metabolic disorders. Early detection is pivotal to survival improvement. Although blood biomarkers have been used in its early diagnosis, missed diagnosis and misdiagnosis still exist due to the heterogeneity of lung cancer. Integration of multiple biomarkers or trans-omics results can improve the accuracy and reliability for lung cancer diagnosis. As metabolic reprogramming is a hallmark of lung cancer, metabolites, specifically lipids might be useful for lung cancer detection, yet systematic characterizations of metabolites in lung cancer are still incipient. The present study profiled the polar metabolome and lipidome in the plasma of lung cancer patients to construct an inclusive metabolomic atlas of lung cancer. A comprehensive analysis of lung cancer was also conducted combining metabolomics with clinical phenotypes. Furthermore, the differences in plasma lipid metabolites were compared and analyzed among different lung cancer subtypes. Alcohols, amides, and peptide metabolites were significantly increased in lung cancer, while carboxylic acids, hydrocarbons, and fatty acids were remarkably decreased. Lipid profiling revealed a significant increase in plasma levels of CER, PE, SM, and TAG in individuals with lung cancer as compared to those in healthy controls. Correlation analysis confirmed the association between a panel of metabolites and TAGs. Clinical trans-omics studies elucida...